H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock

Published on 10/15/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 6, 2026. Gyre Therapeutics stock costs EUR 5.83 on October 15, 2026 at 7:17 p.m. CEST at Lang & Schwarz.

Analyst target and reporting date

H.C. Wainwright reiterated a USD 18.00 target on October 6, 2026.
Gyre Therapeutics is estimated to report third-quarter results on November 6, 2026.
Gyre Therapeutics stock costs EUR 5.83 at Lang & Schwarz on October 15, 2026 at 7:17 p.m. CEST.

GYRE, US4037831033, Illustration mit AI erstellt.

H.C. Wainwright reiterated a Buy rating and a USD 18.00 price target for Gyre Therapeutics on October 6, 2026, according to The Globe and Mail. Gyre Therapeutics stock was trading at EUR 5.83 at Lang & Schwarz on October 15, 2026 at 7:17 p.m. CEST.

The next report is dated

Gyre Therapeutics is estimated to report its third-quarter 2026 results on November 6, 2026, before the US market opens. The conference call is scheduled for 9:30 a.m. ET, according to MarketBeat. The date gives investors a defined point for testing the company's commercial performance and development pipeline.

Revenue and earnings set the test

Gyre reported USD 29.11 million in revenue for the second quarter of 2026, compared with USD 26.49 million expected. Adjusted for the reported accounting basis, diluted earnings per share were negative USD 0.12, missing the USD 0.06 consensus estimate, according to MarketBeat. The contrast between revenue above expectations and a wider loss leaves the November report focused on earnings quality.

Range and valuation

The latest US quote was USD 6.51 on October 15, 2026 at 1:24 p.m. ET. Gyre's 52-week range is USD 5.44 to USD 9.42, while its market capitalization is USD 690.4 million. The price-to-earnings ratio is negative 32.26. Gyre Therapeutics operates in healthcare biotechnology and develops small-molecule treatments for inflammatory and fibrotic diseases.

Market position and dates

Gyre is listed on Nasdaq under the ticker GYRE. The USD 18.00 H.C. Wainwright target remains a separate reference from the EUR quote used for German investors, because the two prices belong to different currencies and venues. The company has also scheduled its third-quarter results for November 6, 2026, before market open.